EU/3/03/163

Table of contents

About

On 2 October 2003, orphan designation (EU/3/03/163) was granted by the European Commission to Prof. Dr. A. A. Roscher, Germany, for 5,6,7,8 tetrahydrobiopterin for the treatment of hyperphenylalaninemia.
The sponsorship was transferred to Orphanetics Pharma Entwicklungs GmbH, Austria, in December 2005.

Key facts

Active substance
5,6,7,8-Tetrahydrobiopterin
Disease / condition
Treatment of hyperphenylalaninaemia
Date of first decision
02/10/2003
Outcome
Positive
EU designation number
EU/3/03/163

Sponsor's contact details

Orphanetics Pharma Entwicklungs GmbH
Innrain 66
6020 Innsbruck
Austria
Telephone: +43 512 57 98 23 42 90
Telefax: +43 512 57 98 23 42 91
E-mail: barbara.brunnhuber@orphanetics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating